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Ursolic acid exerts anti-cancer 
activity by suppressing vaccinia-
related kinase 1-mediated damage 
repair in lung cancer cells
Seong-Hoon Kim1, Hye Guk Ryu1, Juhyun Lee2, Joon Shin3, Amaravadhi Harikishore3, 
Hoe-Yune Jung2, Ye Seul Kim1, Ha-Na Lyu1, Eunji Oh4, Nam-In Baek4, Kwan-Yong Choi2, 
Ho Sup Yoon3,5 & Kyong-Tai Kim1,2
Many mitotic kinases have been targeted for the development of anti-cancer drugs, and inhibitors 
of these kinases have been expected to perform well for cancer therapy. Efforts focused on selecting 
good targets and finding specific drugs to target are especially needed, largely due to the increased 
frequency of anti-cancer drugs used in the treatment of lung cancer. Vaccinia-related kinase 1 (VRK1) 
is a master regulator in lung adenocarcinoma and is considered a key molecule in the adaptive 
pathway, which mainly controls cell survival. We found that ursolic acid (UA) inhibits the catalytic 
activity of VRK1 via direct binding to the catalytic domain of VRK1. UA weakens surveillance 
mechanisms by blocking 53BP1 foci formation induced by VRK1 in lung cancer cells, and possesses 
synergistic anti-cancer effects with DNA damaging drugs. Taken together, UA can be a good anti-
cancer agent for targeted therapy or combination therapy with DNA damaging drugs for lung cancer 
patients.
Tumorigenesis involves uncontrolled cell division, growth, and proliferation, all of which are usually 
caused by malfunction of certain enzymes. Kinase enzymes, in particular, are critically important for 
cell division, a complex process that depends on the coordinated action of various kinases over a short 
period of time. Because these mitotic kinases precisely control cell division, alterations in their activity 
result in abnormal cellular phenotypes, and many researchers interested in the treatment of cancer have 
focused on their function. Specifically, mitotic kinases such as the cyclin-dependent kinases (CDKs), 
the polo-like kinases (PLKs), and the Aurora kinases modulate mitotic progression, and defects in these 
proteins lead to mitotic arrest, and ultimately to cell death1. Although many mitotic kinase blockers have 
been developed, these are unable to kill cancer cells selectively with limited dosing2. In most cases, it 
was found that the amount of drug required to kill cancer cells also kills normal proliferating cells in the 
bone marrow, colon, and other proliferating tissues.
Despite this hurdle, mitotic kinases are still considered to be good therapeutic targets because of 
a cancer-specific feature known as “oncogene addiction”. Normal cells adopt a variety of pathways for 
cell survival and, therefore, cannot be killed by disturbing one particular pathway. Conversely, cancer 
cells are usually dependent on one particular pathway for survival. Thus, if it was possible to identify, 
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and block, the critical pathway for a specific cancer, the cancer cells could be specifically targeted and 
killed. Normal cells would be unaffected because they can adapt to utilize another pathway and survive. 
Notably, the cancer-addicted pathway often includes mitotic kinases, and therefore, the identification 
of cancer-addicted oncogenes has been extremely important for the development of targeted therapies. 
In other words, the identification of ‘druggable’ target genes in specific tumors has been a key area of 
investigation.
The survival rate for lung cancer patients over a 5-year span is lower than that for the majority of 
other cancer patients, and the development of new therapies to increase long-term survival has been 
slow3,4. Thus, the identification of molecular targets related to lung cancer may be a key to improve 
survival rates. Recent work has focused on vaccinia-related kinase 1 (VRK1) as a possible drug target 
for lung cancer treatment. Earlier studies corroborated that VRK1 plays an important role in the lung 
cancer-specific cell cycle network5. VRK1 controls cell division during mitosis by phosphorylating histone 
H3 on Thr3 and Ser106, which is required for chromosome condensation, and also by phosphorylating 
barrier-to-autointegration factor (BAF) at Thr2, Thr3, and Ser4, it regulates nuclear envelope formation 
and dismantling7–9. Additionally, VRK1 contributes to the G1 to S phase transition by phosphorylating 
CRE binding protein (CREB)10. It phosphorylates several key transcription factors involved in cell divi-
sion, including c-Jun11 and activating transcription factor 2 (ATF2)12 and has further been associated 
with G0 exit and G1 entry13. VRK1 is also a well-known DNA damage repair protein that phosphoryl-
ates p53 at Thr18, a key residue for binding with the negative regulator and E3 ubiquitin-protein ligase 
mouse double minute 2 homolog (MDM2)14. During the ionizing radiation (IR)-induced DNA damage 
response (DDR), VRK1 also plays a role in formation of 53BP1 foci15, a damage controlling complex. 
Consequently, these critical roles for VRK1 suggest that it could be an excellent candidate for lung cancer 
therapy.
Many plants synthesize compounds to protect themselves, and these molecules are often used for the 
development of drugs and pharmaceutical agents, as well as in food and cosmetics16. Natural compounds 
have been a major focus of efforts to develop drugs for many diverse diseases, particularly as greater 
than 70% of modern anti-cancer drugs are derived from or structurally related to natural compounds16. 
Therefore, we assayed a natural compound library and selected candidates that inhibit the function of 
the druggable’ target, VRK1. Among the several compounds that were identified, UA showed specific 
inhibitory effect against VRK1.
UA is well known to induce autophagy, anti-inflammation17,18 and apoptosis by suppressing activities 
of various molecules such as COX2, iNOS, MMP-9, STAT3 and NF-κB19–24. Anti-cancer effects of UA 
have been also reported in a variety of cancers including breast, leukemia, prostate, skin, and liver can-
cers21,25–28. However, target protein of UA and its cellular mechanism remain elusive.
In this study, we studied molecular characteristics of UA as a candidate inhibitor of VRK1 and its 
molecular basis of inhibition through nuclear magnetic resonance (NMR) spectroscopy and surface 
plasma resonance (SPR). Finally, we showed that simultaneous treatment of cancer cells with UA and 
DNA damaging drugs generates synergistic effects and confirms these findings in a mouse xenograft 
model.
Results
Inhibition of VRK1 kinase activity by UA. We screened a natural compound library to identify 
VRK1 inhibitors and found several candidate compounds that were able to inhibit the catalytic activity 
of VRK1. Among these, we selected UA (Fig. 1a) because of its strong inhibitory effect against VRK1, as 
compared to other compounds. We performed an in vitro kinase assay (Fig. 1b) and observed that, in a 
concentration-dependent manner, UA can inhibit VRK1 auto-phosphorylation, as well as the phospho-
rylation of histone H3, a known substrate for VRK1. The inhibition curves against both phospho-H3 
and phospho-VRK1 were co-related (Fig. 1c), suggesting that UA inhibits VRK1-mediated kinase activity 
in vitro.
VRK1 acts as a mitotic kinase to promote cell cycle progression by phosphorylating various sub-
strates, such as histone H3, CREB, and BAF during each phase of the cell cycle6,7,10. This prompted us to 
examine UA’s ability to inhibit the catalytic activity of VRK1 in cell culture, as well as in vitro. To this end, 
we employed CREB and histone H3, two representative VRK1 substrates, in lung cancer cells. We showed 
that UA can inhibit the VRK1-mediated phosphorylation of both CREB and histone H3 in vivo, in a 
concentration-dependent manner (Fig. 1d,e). CREB is a transcription factor that promotes expression of 
cyclin D1 (CCND1), which is itself a cofactor of the CDK4/6-CCND1 complex at the G1/S transition10. 
To confirm that UA suppresses CREB phosphorylation, we then measured the levels of CCND1 mRNA. 
Consistent with the decrease in phospho-CREB (p-CREB) levels, CCND1 mRNA levels also decreased in 
response to UA treatment in a concentration-dependent manner in lung cancer cells (Fig. 1f), suggesting 
that UA blocks the VRK1 downstream signaling pathway, as well as its enzymatic activity.
We further observed that the UA-mediated inhibition of histone H3 phosphorylation in lung cancer 
cells was time-dependent (Fig.  1g). Similar to other mitotic kinases, the phosphorylation of substrates 
by VRK1 oscillates during the progression of the cell cycle. Because inhibitors of these kinases would 
show effects only at specific cell cycle phases, their inhibitory activity in asynchronous cells is often 
time-dependent, and accordingly, UA also shows a time-dependent inhibitory effect against VRK1.
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Direct binding of UA to the active site of the VRK1 kinase domain. Because we observed that 
UA inhibits the kinase activity of VRK1 in vitro and in cell culture, we wanted to further to under-
stand the molecular basis of this inhibition. Interestingly, the kinase activity of VRK1 is decreased 
in a dose-dependent manner by UA treatment in vitro, suggesting that other factors are not required 
(Fig. 1b). This result further implies that UA inhibits the kinase activity of VRK1 via direct interactions 
with this protein.
Our previous structural studies provided active site information of VRK129. To determine whether UA 
can directly bind to VRK1 and to identify the region of VRK1 bound by UA, we conducted NMR titra-
tion experiments and in silico modeling. Incremental chemical shift perturbations were observed in the 
amino acid residues of VRK1 upon UA binding (Fig. 2a). These residues were identified on the molec-
ular map of VRK1 (Fig.  2b); they were found to be mainly located in the vicinity of catalytic domain 
Figure 1. Inhibitory effect of UA on VRK1 kinase activity. (a) Chemical structure of UA. (b) in vitro 
kinase assay with His-H3 and GST-VRK1 was performed with increasing concentrations of UA (0.0, 25, 50, 
100, 250, or 500 μ M); GST-VRK1 and His-H3 were then stained with Coomassie blue. (c) Quantification 
of VRK1 auto-phosphorylation and histone H3 phosphorylation shown in panel (b). Data represent the 
mean of three independent experiments ± standard error of means (SEMs). (d) Immunoblotting of A549 
cell lysates treated with the indicated concentration (0.0, 10, or 25 μ M) of UA. (e) Immunoblotting of lysates 
from A549 cells treated with the indicated concentration (0.0, 2.5, 5.0, 10, 25, or 50 μ M) of UA.  
(f) Alteration in relative CCND1 mRNA levels after treatment with the indicated concentrations of UA was 
determined by quantitative real-time PCR; CCND1 mRNA levels were normalized to GAPDH mRNA; error 
bars indicate the SEM, and asterisk (*) represents P-value < 0.05. (g) Immunoblotting of A549 cell lysates 
treated with UA for the indicated times (0, 6, 12, 18, or 24 hr).Immunoblotting was performed using the 
indicated antibodies, and GAPDH was used as the loading control in all experiments.
www.nature.com/scientificreports/
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and are involved in ATP binding. Based on in silico modeling, UA was predicted to fit into the vicinity 
of G-loop, catalytic site and C-terminal lobe of VRK1 kinase domain. UA possesses a steroid nucleus 
and a predominantly hydrophobic moiety, with a hydroxyl and carboxyl substitutions at 3, 4a positions 
of steroid nucleus. The 4a-carboxyl moiety on UA was suggested to interact with main chain carbonyl 
atoms of G135 and the side chain carboxyl group and NH atoms of D137 and K140 residues, respectively 
via hydrogen bonding interactions (Fig. 2c). In addition, the 3-hydroxyl moiety on UA was predicted to 
be engaged in hydrogen bonding with main chain amide atoms of D197 residue (Fig.  2c). The steroid 
nucleus was mainly involved in strong hydrophobic interactions with F48 (G-loop); F134, L184 (in the 
vicinity of DRF motif); V69, I51 and K71 residues that outline the kinase domain. Taken together, these 
interactions might firmly lock or stabilize the ligand binding and inhibition of VRK1 kinase activity.
Next, in order to measure binding affinity between UA and VRK1, we performed SPR with recombi-
nant His-VRK1 protein and the small molecule UA (Fig. 2d). We observed dissociation constants in the 
nM range, indicating that these molecules bind one another with a high affinity, similar to the binding 
observed between other drugs and their targets (Table 1).
Figure 2. NMR titration assay and in silico modeling for interaction of UA with VRK1. (a) NMR 
titration experiments with VRK1 and UA. Spectrum of chemical shift perturbations versus amino acid 
residues of the VRK1 protein after binding of UA. (b) Mapping of chemical shift perturbations on the VRK1 
protein. Most of the perturbed residues (shown in red) are located close to the catalytic domain of VRK1. 
(c) Binding pose of UA into active site of VRK1 kinase domain. The carboxyl moiety on UA interacts with 
main chain carbonyl atoms of G135, side chain atoms of D137 and K140 residues via hydrogen bondings. 
Likewise the 3-hydroxyl moiety is also engaged in hydrogen bonding interaction with D179 main chain 
amide atoms. The steroid nucleus makes strong hydrophobic interactions with F48, F134, L184, V69, I51 
and K71 residues that outline the VRK1 kinase domain (d), SPR detection for the interaction of UA with 
VRK1. The data were obtained by kinetic titration method with sequential injection of analytes without 
regeneration steps.
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UA induces accumulation of DNA damage by inhibiting VRK1. VRK1 is a kinase involved in 
the DDR and DNA damage repair. It interacts with, and phosphorylates, p53 at Thr-18, which is critical 
for increasing p53 protein levels by disrupting the interaction between p53 and the E3 ubiquitin ligase 
MDM214,30,31. VRK1 is also known to be involved in 53BP1 foci assembly, by acting as an essential scaf-
fold protein to recruit DNA repair proteins after IR-induced damage15. Cells are continually afflicted by 
endogenous stressors, including the by-products of metabolic pathway and replication stress32. Thus, the 
loss of proteins involved in the surveillance system required for detection of DNA damage could cause 
such damage to accumulate, even in the absence of exogenous damage. For example, PLK1 is involved 
in the homologous recombination repair system by phosphorylating Rad51, and the loss of PLK1 causes 
DNA damage accumulation, without exogenous damage33. Further, elevated levels of γ -H2A.X, an early 
marker for DNA double-stranded breaks (DSBs), have been reported in the testes of VRK1-deficient 
mice34. For these reasons, we predicted that a VRK1 inhibitor might cause accumulation of DNA damage 
by blocking the function of VRK1 in DDR. In accordance with this, we observed that in lung cancer cells, 
the siRNA mediated loss of VRK1 also generates γ -H2A.X, suggesting that a lack of VRK1 induces DSBs 
by interfering with the repair system (Fig. 3a,b). Because UA blocks VRK1 kinase activity, we predicted 
that treatment with this molecule would also lead to elevated γ -H2A.X, and as expected, we found that 
UA treatment induces γ -H2A.X in lung cancer cells (Fig. 3c,d), suggesting that UA leads to the accumu-
lation of DNA damage by blocking the kinase activity of VRK1.
Under IR, VRK1 is required to recruit 53BP1 to the site of DSBs, and defective VRK1 cannot assem-
ble these 53BP1 foci during the DDR15. Because UA inhibits VRK1 activity, we analyzed UA-induced 
53BP1 foci disassembly. Treatment with the DNA damage-inducing drug, etoposide, leads to enhanced 
53BP1 foci formation, as well as γ -H2A.X foci generation. The DNA damage was confirmed to be due 
to etoposide treatment, and the DNA damage repair proteins were recruited to the site of DNA damage, 
indicating that under these conditions, the repair system is normally activated. In contrast to the etopo-
side treatment, 53BP1 was not recruited to the DNA damage site after UA treatment (Fig. 3e), suggesting 
that UA facilitates DNA damage accumulation by preventing the recruitment of repair proteins.
Synergistic effects of UA with DNA damaging drugs. Cancer cells often depend on specific genes 
that are essential for cell survival. These target genes could be particularly vulnerable in specific situa-
tions, such as in the presence of DNA damage or metabolic stress35,36. That is, the gene products may act 
to buffer the effect of stressors/damage; however, if these buffering effects are diminished by mutation or 
an inhibitor, the cancer cells may be unable to tolerate consistent damage and would eventually undergo 
cell death37. For example, cancer cells with defective pRB or a mutated E2F1 are more sensitive to drugs 
that elicit DNA damage38–41. It has also been shown that DNA damage inducers render VRK1-deficient 
lung cancer cells more vulnerable because of the role of VRK1 in DDR5,14,15,31,42,43. Thus, we hypothesized 
that UA-induced VRK1 inhibition would render lung cancer cells more susceptible to DNA damage. We 
found that treatment of lung cancer cells with UA, combined with doxorubicin, decreases cell viability 
more than either compound alone (Fig. 4a). Specificaclly, the EC50 for doxorubicin with 24hr incubation 
was measured to be 56.64 μ M, and this EC50 was decreased to 6.14 when cells were also treated with 
25 μ M UA. The combination index, an indicator of synergistic effects between drugs, was found to be 
0.66, suggesting that UA-induced VRK1 inhibition has synergistic effects with doxorubicin (Table 2). To 
investigate whether another drug associated with the inhibition of DNA damage repair genes displays 
synergistic effects with UA, we incubated UA-treated cells with veliparib, a PARP-1 inhibitor44. Although 
treatment with veliparib alone does not show a cell-killing effect, incubation with veriparib and UA 
results in a significant decline in cell viability (Fig. 4b).
Synergistic effects of UA with Doxorubicin in a xenograft mouse model. Finally, to deter-
mine whether the synergistic effects between UA and DNA damaging agents occurs in vivo, we uti-
lized a xenograft mouse model and performed live imaging to monitor change in tumor size over time. 
LLC-luciferase cells were injected subcutaneously into the right flank of male BL/6 mice, and the indi-
cated drugs were then intra-peritoneally injected in ventral region of each mouse. We found that after 
10 days, although the overall tumor volume was increased in the control group, the volume of tumors in 
drug treatment group was smaller than tumors in control group. The group treated with UA and doxoru-
bicin, in particular, showed a high synergistic effects (Supplementary Figure S1). To confirm synergistic 
effects between UA and the DNA damage-inducing drug, etoposide, we injected LLC-luciferase cells into 
BL/6 mice, and then injected the indicated drugs, as described above. We then measured tumor weight ex 
vivo, and found that, like doxorubicin, etoposide has synergistic effects with UA (Fig. 4c). These results 
suggest the possibility of developing VRK1 inhibitors as potential anti-cancer therapeutics.
ka (M−1s−1) kd (s−1) KD
Ursolic acid 21.75 1.59 × 10−5 731 nM
Table 1.  Dissociation constants of UA on VRK1.
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Discussion
Previous studies have reported that UA, ((1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2, 
6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic 
acid), a pentacyclic triterpene acid that is widely found in vegetables, inhibits inflammation and upregu-
lates autophagy17,18. Anti-cancer effects of UA were also reported in a variety of diseases, including breast 
Figure 3. Disruption of DNA damage-induced 53BP1 foci formation by UA. (a) Immunocytochemistry 
of A549 cells transfected with siVRK1 or siCon. (b) Quantification of γ -H2A.X positive cells shown in 
panel (a). (c) Immunocytochemistry of A549 cells treated with UA or DMSO control. (d) Quantification 
of γ -H2A.X positive cells shown in panel (c). (e) Immunocytochemistry of A549 cells treated with the 
indicated compounds. The cells in each group were stained with indicated antibodies and Hoechst, and all 
images were visualized by confocal laser scanning microscopy. P-value was calculated using the Student’s 
t-test. **P < 0.01, ***P < 0.001.
www.nature.com/scientificreports/
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cancer, leukemia, prostate cancer, lung cancer, melanoma, and endometrial cancer. Specifically, UA was 
found to inhibit tumor proliferation and tumor cell differentiation, and to induce apoptosis and exert 
anti-angiogenesis effects17,45–52. The target protein of UA, however, has remained unknown, and therefore, 
its cellular mechanism has been elusive.
In this study, we identified a target protein for the action of UA and its cell-killing mechanism. We 
showed that UA binds directly to the catalytic domain of the mitotic kinase, VRK1, and inhibits its kinase 
activity in vitro and in cell culture. By measuring 53BP1 foci formation, we found that UA inhibits the 
DNA damage defense activity of VRK1 and induces lung cancer cell death. In addition, we showed that 
co-treatment of lung cancer cells with UA and DNA damaging drugs effectively triggers a more severe 
cell death than treatment with either UA or drug alone. Finally, we confirmed the synergistic effects 
between UA and DNA damage-inducing drugs in vivo in a xenograft mouse model.
DNA damage triggers severe cellular injury, and in order to quickly recover from this assault, cells 
require a DNA repair system. Kinases play important roles in DNA repair systems because they have 
the ability to rapidly propagate the damage signal and to induce immediate reaction. In the DDR, the 
kinase VRK1 interacts with p53, forming a basal complex, and immediately stabilizes p53 on DNA dam-
age signal31. VRK1 phosphorylates p53 at Thr-18, stabilizing the protein and promoting p53-mediated 
transcription. This leads to elevated expression of genes mediating cell cycle arrest, DNA damage repair, 
and apoptosis14,30,42,43. In addition to p53, c-jun is phosphorylated at Ser-63 and Thr-73 by VRK1, and 
phosphorylated c-jun turns on DDR-related genes11. Furthermore, VRK1 is involved in the recruitment 
of repair proteins to the sites of DNA damage. In the alternative non-homologous end joining repair 
Figure 4. Synergistic effects between UA and the DNA damaging drug. (a) Cell viability of A549 cells 
treated with, or without, doxorubicin and UA. Cell viability was detected with MTT (n = 10). (b) Cell 
viability of A549 cells treated with, or without, veliparib and UA. Cell viability was detected with MTT 
(n = 10). (c) Quantification of ex vivo mouse tumor weight after treatment with the indicated compound. P-
value was calculated using the one-way ANOVA. *P < 0.05, ***P < 0.001.
Drugs EC50 (μM) Notes
Ursolic acid 39
Doxorubicin 57
Doxorubicin (in combination 
with 25 μ M Ursolic acid 6
Combination 
index = 0.7
Table 2.  The EC50 values of Ursolic acid and doxorubicin in A549 cells.
www.nature.com/scientificreports/
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process, 53BP1 foci are required to recruit other repair proteins, and VRK1 participates in formation 
of 53BP1 foci in response to DNA DSBs induced by IR15. Because VRK1 functions as an early warning 
signal through interactions with various other proteins, we expect that UA can be exploited to help elu-
cidate the early response to DNA damage.
VRK1 has been reported to be upregulated in actively dividing cells and in cancer cells, and it is 
known to be required for G0 exit13,53,54. VRK1 induces cyclin D1 expression by phosphorylating CREB 
in the G1/S transition, and it is also involved in chromatin compaction by histone H3 in the G2/M 
transition6,10. Further, VRK1 deficiency results in infertility due to a progressive loss of spermatogonia 
in male mice and a defect of folliculogenesis in female mice55–58. VRK1 is one of the key molecules to 
orchestrate both mitosis and meiosis, and it is an indispensable protein to study cell proliferation and 
sterility. Therefore, UA, which specifically blocks VRK1, may also help to further understand tumor 
formation and reproductive sterility.
The nuclear envelope is a structure that segregates the nucleus from cytosol, and its disruption causes 
cellular catastrophe. Thus, the dynamics of the nuclear envelope determine cell fate. The nuclear envelope 
is composed of lamin scaffold proteins and other lamin-associated proteins, which help support the enve-
lope structure59. A defect in these proteins results in an abnormal nuclear envelope and triggers a devas-
tating disorder known as progeria syndrome60. Among the lamin-associated proteins, BAF, in particular, 
participates in nuclear dynamics. Its unique upstream kinase, VRK1, regulates nuclear envelope break-
down, reassembly, and support of the nuclear structure7,9,61. Defects in VRK1 cause abnormal nuclear 
envelope structure, likely due to altered BAF function62. This suggests that VRK1 is an attractive target 
in the treatment of cancer, as cancer cells have abnormally fragile nuclear structure and are susceptible 
to killing under conditions that disturb nuclear envelope dynamics63. We have tested this by employing 
small molecule VRK1 inhibitors that inhibit the VRK1-mediated BAF phosphorylation and consequently 
prevent nuclear envelope break down or reassembly in cancer cells, suggesting that inhibition of VRK1 
renders cancer cells, which contain underlying nuclear envelope defects, more vulnerable64,65.
Although many small molecules have multiple targets, a VRK1 inhibitor may have more specificity 
due to the fact that VRK1 has a unique kinase domain, distinct from that of other kinase proteins29. 
Thus, a specific inhibitor of VRK1 may have less cross reactivity with other kinases and fewer unde-
sirable effects. Further, VRK1 proteins also have reduced sensitivity to most inhibitors66,67; however, 
current inhibitors of VRK1 have not taken advantage of this circumstance68,69. Here, we show that UA 
(KD = 731 nM, EC50 = 39 μ M) has a stronger binding affinity with VRK1 and a lower EC50 against lung 
cancer cells than luteolin (KD = 5.8 μ M, EC50 = 59 μ M) and other VRK1 inhibitor69. Although UA itself 
might not be sufficient for specific VRK1 inhibition in vivo, employing de novo structure-based drug 
design methods or fragment-based approaches at the interacting residues with UA or exploiting struc-
tural analogs of UA could facilitate development of novel drugs for the treatment of lung cancer, with 
minimal side effects.
Materials and Methods
Chemicals and Reagents. Analytical grade UA, etoposide and doxorubicin were purchased from 
Sigma-Aldrich (St. Louis, MO, USA), veliparib was purchased from Selleckchem (Houston, TX, USA), 
and these compounds were prepared in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and further diluted 
in culture medium. The final concentration of DMSO was kept at ≤ 1 μ l/ml. [32P-γ ] ATP was purchased 
from Perkin Elmer/NEN (Waltham, MA, USA), and recombinant histone H3 was purchased from Roche 
Applied Science (Indianapolis, IN, USA). Other recombinant proteins, such as glutathione sulfotrans-
ferase (GST), GST-VRK1, and His-BAF were expressed in Escherichia coli (BL21) and were purified by 
affinity chromatography. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody was purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and histone H3 phospho-Ser10 antibody was 
purchased from Abcam (Cambridge, UK). Antibodies to phospho-CREB and CREB were obtained from 
Cell Signaling Technology (Danvers, MA, USA), and those against 53BP1 and γ -H2A.X were purchased 
from Upstate Biotechnology Inc. (Lake Placid, NY, USA). Hoechst 33342 and CNBr-Sepharose 4B were 
obtained from Sigma-Aldrich.
Protein kinase assay and immunoblot. An in vitro kinase assay was performed in accordance 
with methods previously described elsewhere64. In brief, the in vitro kinase assays were performed in 
kinase buffer (50 mM MOPS, pH 7.2, 25 mM β -glycerophosphate, 10 mM EGTA, 4 mM EDTA, 50 mM 
MgCl2, 0.5 mM DTT) containing γ -ATP (PerkinElmer), with GST-VRK1 and its substrates, includ-
ing His-H3 (Fig.  1b). Reactions were carried out for 30 min at 30 °C. Radioactivity incorporation was 
detected by autoradiography. The quantities of proteins used in kinase assays were measured by using 
Coomassie blue (Bio-Rad, Hercules, CA, USA). Immunoblot analysis was performed as we previously 
described elsewhere64. For immunoblot analysis, bands were visualized using the Western blot detection 
kit (Neuronex, Pohang, South Korea).
Surface plasma resonance. SPR was performed as previously described64. His-VRK1 was used as 
the ligand, and UA was used as the analyte.
www.nature.com/scientificreports/
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Confocal microscopy. A549 cells transfected with control siRNA (siCon) or siRNA directed against 
VRK1 (siVRK1) were grown on a microscope slide, and then treated with 50 μ M UA or 10 μ M etoposide 
for 12 h. The cells were fixed with paraformaldehyde and permeabilized with 10% fetal bovine serum 
(FBS; HyClone Laboratories, Logan, UT) in phosphate buffered saline (PBS). Subsequently, cells were 
stained with indicated antibodies, and the DNA was stained with Hoechst. The cells were then observed 
using confocal microscopy (Fluoview FV1000; Olympus, Tokyo, Japan).
Cell Culture. Lewis lung carcinoma cells labeled with a luciferase reporter were obtained from G-one 
Ahn (Postech, Pohang, Korea). Additionally, A549 cells, which have been previously described, were used 
in this study64. Both cell types were cultured in an RPMI 1640 medium, DMEM high glucose (HyClone) 
containing 10% FBS (HyClone) and 1% penicillin/streptomycin (Welgene, Daegu, Korea) in a humidified 
5% CO2 incubator at 37 °C.
Transfection. Transient transfection was performed by a microporator MP-100 (Invitrogen, Carlsbad, 
CA) according to manufacturer instructions.
Quantitative reverse transcription polymerase chain reaction (RT-PCR). A549 cells were 
treated with UA at the indicated concentration for 12 h. Total RNA from A549 cells was prepared using 
the TRI Reagent (Molecular Research Center, Cincinnati, OH, USA) according to the manufacturer 
instructions, and this was reverse transcribed to generate complementary DNA (cDNA). Quantitative 
RT-PCR was performed using the SYBR Green PCR mix (Takara Bio Inc., Shiga, Japan) and a real-time 
detector system (Applied BioSystems, Foster City, CA USA); GAPDH levels were used as a control to 
normalize transcript levels.
Plasmids, recombinant protein purification. To generate the BAF and VRK1 expression con-
structs, full-length BAF and VRK1 were amplified by PCR from HeLa cells, and each DNA fragment was 
cloned into pEGFP-C1, pDsRed-Monomer-N1, and pProEX (Clontech, Amersham) vectors. To purify 
recombinant His-VRK1 and His-BAF, pProEX-VRK1 and pProEX-BAF, respectively, were transformed 
into E. coli (BL21), and each protein was purified using Ni-NTA beads (Invitrogen).
Ligand docking assay. A homology model developed from the X-ray crystal structure of VRK1 was 
employed to assess the molecular interaction and the binding mode of newly identified VRK1 leads. In 
the present study, the model structure was energy minimized for 5,000 steps by the CHARM force-field 
and conjugate gradient method in the Discovery Studio 3.0 suite29. The 3-D coordinates of UA were pre-
pared using the Prepare Ligand module and energy minimized for 2,000 steps using the Smart Minimizer 
algorithm in the Discovery Studio 3.0 suite. The molecular docking program GOLD 5.0 was employed 
to assess the binding mode of the VRK1 leads. Our previous NMR binding studies have identified the 
key residues that are perturbed upon ligand binding; these were used to define the active site29. Default 
settings and scoring functions, the GOLD PLP and GOLD scoring function, were employed to score 
docking interactions and their probable docking mode of binding.
Cell viability assay. Cells were treated for 24 h with indicated compounds (UA, doxorubicin and veli-
parib) or with DMSO as a control. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetarazolium bromide (MTT) assay according to the manufacturer’s protocol. The half-maximal 
effective concentration (EC50) was determined using GraphPad Prism (GraphPad, San Diego, CA, USA). 
The combination index was calculated using the following equation: combination index = (UA) m50/(UA) 
s50+ doxorubicin) m50/(doxorubicin) s50, where (X) m50 is the concentration of drug X that will produce 
a 50% inhibitory effect in the combination; and (X) s50 is the concentration of drug X that will produce 
the same level of effect by itself. Combination index > 1 indicates antagonism; combination index < 1 
indicates synergy; and combination index = 1 indicates an additive effect70.
Statistical Analysis. The Student’s paired two-tailed t-test, ANOVA, and repeated measure ANOVA 
were used to determine significance. Values of P < 0.05, P < 0.01, P < 0.001 were indicated by *, **, and 
*** respectively. All error bars shown in this study represent standard deviations.
Mouse experiments. LLC-luciferase cells (1 × 107 cells/mouse) were injected subcutaneously into the 
right flank of C57 BL/6 mice (~6–8 weeks old). One week after injection, mice were split into four groups, 
and administered the following treatments i) DMSO, ii) UA (100 mg/kg) iii) Doxorubicin (2 mg/kg), 
or iv) UA plus doxorubicin. Each group contains four mice. Each compound was injected four times 
during a 10 day span. After injection, on the indicated days, luminescence images were acquired by IVIS 
spectrum (Caliper, Massachusetts, USA) at the Pohang Center of Evaluation of Biomaterials, Pohang 
Technopark, Pohang, Republic of Korea. In ex vivo experiments, etoposide (6 mg/kg) instead of doxoru-
bicin was injected four times over 2 weeks, similar to above, and mice were sacrificed at two weeks after 
first drug injection, and tumor weight of mice was measured.
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Ethics Statement. Approval of the study protocol was obtained from the Pohang University of Science 
and Technology Institutional Animal Care and Use Committee (approval number: 2014-03-0002). All 
animal experiments were carried out according to the provisions of the AnimalWelfare Act, PHS Animal 
Welfare Policy, and the principles of the NIH Guide for the Care and Use of Laboratory Animals. All 
mouse lines were maintained at the POSTECH animal facility under institutional guidelines.
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